Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
Cancer cells possess a remarkable ability to exploit and manipulate cellular pathways to ensure their own survival and proliferation. Among the critical pathways involved, the phosphoinositide 3-kinase (PI3K) pathway plays a significant role. GS-1101, also known as Idelalisib or CAL-101, is a key therapeutic agent that targets a specific component of this pathway, PI3K-delta, thereby disrupting cancer cell survival mechanisms.
GS-1101 is a potent and selective oral inhibitor of PI3K-delta. This specific isoform of PI3K is highly expressed in hematopoietic cells and is critical for the survival and proliferation signals that cancer cells, particularly those in lymphoid malignancies, rely upon. By inhibiting PI3K-delta, Idelalisib effectively interferes with the signaling cascades that promote cancer cell survival. This targeted action helps to halt tumor growth and, in some cases, induce cancer cell death.
The Idelalisib drug mechanism is elegantly designed to disrupt these survival pathways. It blocks the production of PIP3, a molecule that activates downstream targets essential for cell proliferation and survival. This targeted approach, known as PI3K delta targeting cancer therapy, offers a distinct advantage. It aims to spare normal cells that may depend on other PI3K isoforms, thereby potentially reducing the adverse effects often associated with broader pathway inhibitors.
The clinical significance of GS-1101 is underscored by its success in various Idelalisib clinical trials. These studies have demonstrated its efficacy in treating aggressive hematologic cancers like refractory indolent non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. The drug's development has been a testament to the power of understanding specific molecular targets in cancer treatment. For researchers, the ability to purchase Idelalisib facilitates further exploration into its mechanisms and potential combinatorial therapies.
The role of GS-1101 (Idelalisib) in targeting cancer cell survival pathways highlights a major advancement in oncology. By focusing on the precise inhibition of PI3K-delta, this targeted therapy provides a more effective and refined strategy for combating challenging hematologic malignancies, offering renewed hope for patients and advancing the field of precision medicine.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
